The Department of Health is consulting on proposed changes to the governance arrangements for controlled drugs in England and Scotland, including the role and functions of Controlled Drugs Accountable Officers (CDAOs).
The Health and Social Care Act 2012 has introduced significant structural changes for the NHS in England from next April. These have important ramifications for the overall governance of controlled drugs and in particular, for the role and functions of primary care trust CDAOs. Consequently, ‘the Controlled Drugs (Supervision of Management and Use) Regulations 2006′ require revision.
This consultation describes the proposed new regulations and seeks views and comments from all interested parties on a number of proposed changes to the current arrangements.
The proposed new regulations have been devised with the support and help of a small multi-disciplinary working group chaired by Dr Keith Ridge, Chief Pharmaceutical Officer for England.
The consultation runs from 27 September to 15 November 2012.
Comments should be sent, using the reply form at annex B of the consultation document, to robert.allan@dh.gsi.gov.uk
The Department will collate all comments received and publish a summary of the responses on the Department’s website in due course.
Read:
- draft consultation regulations: Controlled Drugs (Supervision of Management and Use) Regulations 2013
- draft regulations: the Controlled Drugs (Supervision of Management and use) Regulations 2013 – consultation document
- draft regulations: the Controlled Drugs (Supervision of Management and use) Regulations 2013 – consultation reply form
- Controlled Drugs (Supervision of Management and Use) Regulations 2013: equality analysis
- Controlled Drug Accountable Officers and “the Controlled Drugs (Supervision of management and Use) Regulations 2006″: impact assessment
- red tape challenge: the Controlled Drugs (Safe Management and Use) Regulations 2006
